Systemic administration of the di-apocarotenoid norbixin (BIO201) is neuroprotective, preserves photoreceptor function and inhibits A2E and lipofuscin accumulation in animal models of age-related macular degeneration and Stargardt disease

Valérie Fontaine; Elodie Monteiro; Mylène Fournié; Elena Brazhnikova; Thinhinane Boumedine; Cécile Vidal; Christine Balducci; Louis Guibout; Mathilde Latil; Pierre J. Dilda; Stanislas Veillet; José-Alain Sahel; René Lafont; Serge Camelo

doi:doi:10.18632/aging.103014

← Back

Research Paper Volume 12, Issue 7 pp 6151—6171

Systemic administration of the di-apocarotenoid norbixin (BIO201) is neuroprotective, preserves photoreceptor function and inhibits A2E and lipofuscin accumulation in animal models of age-related macular degeneration and Stargardt disease

Figure 5. Effect of norbixin early curative supplementation from 9 to 15 months in Abca4^-/- Rdh8^-/- mice. (A) Schematic representation of the 6-month early curative supplementation protocol design. (B) Scotopic A wave, (C) Scotopic B wave, (D) Photopic B wave ERG recorded after 6 months of oral supplementation with norbixin in Abca4^-/-Rdh8^-/- mice compared to mice fed with normal chow (vehicle) and to 1.5 and 9-month-old mice. (E) Quantification of photoreceptor nuclear layers along the superior and inferior poles of the retina each measured every 200 μm apart from the optic nerve. (F) A2E quantification in eyes from 9-month-old Abca4^-/- Rdh8^-/- mice, 15-month-old mice fed with normal chow or with norbixin-containing pellets. Bars represent mean ± s.e.m. with n = 6 per group (i.e. n=12 eyes for the norbixin treated group and n=11 eyes for the vehicle treated group for ERG). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 compared to vehicle (One-way ANOVA, Dunnett's post-test).